A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to ...

Don't ignore those symptoms. Head and neck cancers are far more manageable, and often curable, with less aggressive treatment ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Low-dose computed tomography is more sensitive than chest radiography in detecting lung metastases or second primary lung cancer in patients with HNSCC.

Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients. The Australian cancer-treatment company said Monday the median rate for overall ...

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...